Enavate Sciences
VC Fund
Menlo Park, United States
Enavate Sciences is a VC fund in Menlo Park focused on Therapeutics and Biotechnology. Enavate Sciences is committed to investing in and supporting the strategic growth of innovative therapeutic and enabling technology companies.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 55%
Last updated:
For AI agents: llms.txt
Industries Enavate Sciences invests in
Stages Enavate Sciences invests in
Countries Enavate Sciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christine Del Corsano
|
|||
Edd Fleming
|
|||
James Boylan
|
|||
Robert Glassman
|
|||
1 more contact available
Investment Focus
Industry
- Therapeutics 9 (45%)
- Biotechnology 9 (45%)
- Biopharma 7 (35%)
- Health Care 6 (30%)
- Pharmaceutical 5 (25%)
Stage
- Series B 6 (30%)
- Series A 3 (15%)
- Series C 3 (15%)
- Post-IPO Equity 3 (15%)
- Seed 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Christine Del Corsano
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
Edd Fleming
Executive Vice President, Commercialization
|
Executive Vice President, Commercialization | Total investments: 6 | Find email | |
|
James Boylan
Chief Executive Officer
|
Chief Executive Officer | Total investments: 4 | Find email | |
|
Robert Glassman
EVP, Search and Evaluation
|
EVP, Search and Evaluation | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AirNexis Therapeutics
|
AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M / Series A / Jan 09, 2026 | |
Braveheart Bio
|
Braveheart Bio is a biotechnology startup in late clinical development, working on innovative treatments for hypertrophic cardiomyopathy and related disorders. Braveheart's small molecule therapy candidate, BHB-1893, is a selective cardiac myosin inhibitor designed to improve heart function in HCM patients. Overcontraction in HCM can result inthicker heart muscle and a decline in the heart's ability to fill and pump blood. HCM is among the most frequent uncommon diseases, affecting one in every 500 people in the United States. | $185M / Series A / Nov 05, 2025 | |
BBOT
|
BridgeBio Oncology Therapeutics operates as a biopharmaceutical company. | $261M / Post-IPO Equity / Aug 11, 2025 | |
Normunity
|
Normunity is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer.Based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targetingnewly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer.Normunity is located in Boston, Massachusetts and West Haven, Connecticut. | $75M / Series B / Jan 13, 2025 | |
Aviceda Therapeutics
|
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively. | $207.5M / Series C / Jan 07, 2025 | |
|
Aviceda Therapeutics
|
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively. | $207.5M / Series C / Jan 07, 2025 | |
OrsoBio
|
OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause. | $67M / Series B / Sep 06, 2024 | |
Zenas BioPharma
|
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. | $200M / Series C / May 07, 2024 | |
|
BBOT
|
BridgeBio Oncology Therapeutics operates as a biopharmaceutical company. | $200M / Venture - Series Unknown / May 02, 2024 | |
Sionna Therapeutics
|
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF). | $182M / Series C / Mar 06, 2024 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Enavate Sciences invest in?
Enavate Sciences invests primarily in Therapeutics, Biotechnology and Biopharma startups, most often at Series B and Series A stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Enavate Sciences?
Public channels for Enavate Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Enavate Sciences?
The team at Enavate Sciences includes Christine Del Corsano (Chief Financial Officer), Edd Fleming (Executive Vice President, Commercialization) and James Boylan (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
